BR2251 not checked
BioRay Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “BR2251 low dose, mid dose, high dose, Titration regimen and Take orally once a day”In the company’s words, NCT07498647 on ClinicalTrials.gov
- Tested for
- Gout and Hyperuricemia
- Main trialPhase 2
- “This study is a randomized, double-blind, non-befloxacin-controlled, multicenter, phase II clinical trial, evaluating the efficacy, safety, and pharmacokinetic characteristics of BR2251 tablets when administered multiple times in subjects with primary gout and hyperuricemia. This study is a dose exploration study, including a screening period (up to 2 weeks), a double-blind treatment period (12 weeks), and a follow-up period (2 weeks). The screened subjects were stratified based on whether their serum uric acid (sUA) was less than 480 μmol/L or greater than or equal to 480 μmol/L. They were…”In the company’s words, NCT07498647 on ClinicalTrials.gov
Other drugs for Gout and Hyperuricemia
- DapansutrileOlatec Therapeutics, Inc. · Phase 2/3
- EtoricoxibLaboratorios Silanes S.A. de C.V. · Phase 3
- DotinuradCrystalys Therapeutics · Phase 3
- AR882Arthrosi Therapeutics · Phase 2
- SSGJ-6133SBio · Phase 2
- PRX-115Protalix · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Oct 2026 | Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026